Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

Conditions:   Advaced Solid Tumors;   Melanoma Intervention:   Biological: AK104 Sponsors:   Akeso;   Akeso Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials